China’s Fast‑Follower Model Pressures Biotech IP Strategies

As competition in global new‑drug development intensifies, protecting the core asset of biotech companies—intellectual property (IP)—requires more than robust patents. Experts note that controlling the timing of information disclosure and employing strategic workarounds are also essential. China’s “fast‑follower” model, characterized by a rapid and cost‑effective development environment, is quickly catching up with innovations originating in the United States and other regions, increasing the burden on early‑stage biotech firms. According to the Asia Society, Chinese biotech firms recruit clinical trial patients 2–3 times faster than their U.S. counterparts, and government reforms have reduced clinical approval timelines from 60 days to 30 days. Additionally, clinical costs in China are reported to be 50–60% lower than in the United States. These factors underscore the growing pressure on biotech companies to adapt their IP protection strategies in response to China’s accelerating and economical clinical landscape.